Get the Stockscreener App
0.515
9.67%
0.0454
Bioaffinity Technologies Inc stock is traded at $0.515, with a volume of 464.50K.
It is up +9.67% in the last 24 hours and up +76.37% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$0.4696
Open:
$0.488
24h Volume:
464.50K
Relative Volume:
0.05
Market Cap:
$9.01M
Revenue:
$9.37M
Net Income/Loss:
$-8.45M
P/E Ratio:
-0.6358
EPS:
-0.81
Net Cash Flow:
$-7.27M
1W Performance:
-8.05%
1M Performance:
+76.37%
6M Performance:
-75.82%
1Y Performance:
-82.30%
1-Day Range:
$0.488
$0.5814
1-Week Range:
$0.4615
$0.5814
52-Week Range:
$0.2404
$3.1626
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.515 | 9.01M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
bioAffinity Technologies streamlines lung cancer detection test By Investing.com - Investing.com Canada
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost - BioSpace
bioAffinity Technologies streamlines lung cancer detection test - Investing.com
Bioaffinity Technologies Increases Efficiency Of Cypath Lung Test - marketscreener.com
Revolutionary Lung Cancer Detection Test Achieves 92% Accuracy While Slashing Costs by 25% - Stock Titan
ASP Isotopes and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Corsicana Daily Sun
bioAffinity Technologies Board Member Announces Departure - TipRanks
CyPath Lung Helped Detect Breast Cancer Recurrence - Medical Product Outsourcing
Bioaffinity Technologies Files For Resale Of Up To 3.0 Million Shares Of Common Stock By Selling StockholdersSEC Filing - MarketScreener
bioAffinity Technologies Reports Record Revenue for 2024 - TipRanks
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues - Yahoo Finance
Earnings roundup: Usio back in the black; losses widen at bioAffinity, Wytec - San Antonio Express-News
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Joplin Globe
bioAffinity Technologies Stock Price, Quotes and Forecasts | NASDAQ:BIAF - Benzinga
Best Biotech Stocks To Follow Today – April 1st - Defense World
Biotech stock bioAffinity Technologies, Inc. (NASDAQ: BIAF) Makes NASDAQ Top Percentage Gainer on News - Investorideas.com
Take off with BioAffinity Technologies Inc (BIAF): Get ready for trading - Sete News
bioAffinity Technologies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
bioAffinity Technologies (NASDAQ:BIAF) Given Hold Rating at Maxim Group - Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Lung cancer spit test fast-tracks a San Antonio biotech company for growth - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Nasdaq Surges 1%; US Construction Spending Rises In February - Benzinga
Dow Dips Over 400 Points; ISM Manufacturing PMI Falls In March - Benzinga
What's Going On With BioAffinity Shares Tuesday? - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
bioAffinity Technologies stock hits 52-week low at $0.25 By Investing.com - Investing.com South Africa
bioAffinity Technologies, Inc. SEC 10-K Report - TradingView
bioAffinity Technologies earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
bioAffinity posts 270% revenue rise with Medicare coverage - Investing.com
bioAffinity Technologies stock hits 52-week low at $0.25 - Investing.com
Record-Breaking 270% Revenue Surge: bioAffinity's Growth Story Takes Unexpected Turn - Stock Titan
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - The Joplin Globe
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer - BioSpace
BIOAFFINITY TECHNOLOGIES Earnings Preview: Recent $BIAF Insider Trading, Hedge Fund Activity, and More - Nasdaq
Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer - Business Wire
New Clinical Data: CyPath Lung Test Proves Vital in Early Cancer Detection, Saves Millions - Stock Titan
bioAffinity Technologies (NASDAQ:BIAFW) Shares Down 24.3% – Here’s What Happened - Defense World
bioAffinity stock hits 52-week low at $0.26 amid market challenges - Investing.com Australia
BioAffinity Technologies Inc (BIAF): An Important Analyst Insights - Stocks Register
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence - BioSpace
bioAffinity stock hits 52-week low at $0.26 amid market challenges By Investing.com - Investing.com South Africa
bioAffinity Technologies Cutting Jobs to Save $4 Million in Operating Costs - MPO-mag
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million - Business Wire
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer - Joplin Globe
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):